An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Nov 2023 Status changed from recruiting to completed.
- 01 Apr 2022 New trial record
- 19 Feb 2022 According to results presented at the 2022 Genitourinary Cancers Symposium, recruitment of this is ongoing until Jan 2022 and follow-up until July 2023.